Poliomyelitis Clinical Trial
Official title:
Immunogenicity and Safety of Fractional Booster Dose of Sanofi Pasteur's Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally Versus Full Booster Dose of Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intramuscularly at 15 to 18 Months of Age in Healthy Toddlers in The Philippines
The purpose of this study is to investigate the use of a fourth fractional booster dose of
sanofi pasteur's IMOVAX Polio injected intradermally (using the Mantoux technique) as
booster dose between 15 to 18 months of age, in terms of immunogenicity and safety.
Objectives:
- To describe in each group the immunogenicity of IMOVAX Polio administered intradermally
or intramuscularly, one month after the booster dose given at 15-18 months of age in
toddlers previously primed with three doses of IMOVAX Polio vaccine during the IPV25
study.
- To describe in each group the safety of the booster dose of IMOVAX Polio vaccine
administered intradermally or intramuscularly.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04989231 -
An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
|
||
| Completed |
NCT00352963 -
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
|
Phase 3 | |
| Recruiting |
NCT03890497 -
Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh
|
Phase 4 | |
| Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
| Completed |
NCT04693286 -
Clinical Trial of Novel OPV2 Vaccine
|
Phase 2 | |
| Completed |
NCT02847026 -
Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study
|
Phase 4 | |
| Completed |
NCT02189811 -
Polio End-game Strategies - Poliovirus Type 2 Challenge Study
|
Phase 4 | |
| Completed |
NCT01444781 -
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
|
Phase 3 | |
| Completed |
NCT01214889 -
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
|
Phase 3 | |
| Completed |
NCT00879827 -
Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants
|
Phase 3 | |
| Completed |
NCT01457495 -
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly
|
Phase 2 | |
| Completed |
NCT02853929 -
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
|
Phase 4 | |
| Completed |
NCT03614702 -
Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV
|
Phase 3 | |
| Terminated |
NCT04063150 -
Immunogenicity of Intramuscular and Intradermal IPV
|
Phase 4 | |
| Completed |
NCT04614597 -
A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China
|
||
| Completed |
NCT03239496 -
A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
|
Phase 3 | |
| Completed |
NCT04544787 -
A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates
|
Phase 2 | |
| Completed |
NCT02985320 -
Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine
|
Phase 1/Phase 2 | |
| Completed |
NCT02291263 -
Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine
|
Phase 3 | |
| Completed |
NCT02274285 -
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants
|
Phase 3 |